Brain Tumours and Sarcomas: Crossing the Barrier and Targeting the Rare
Two of oncology's hardest problems share a theme: getting the right molecule to a place it cannot easily reach. In the brain, the barrier that protects us becomes the tumour's shield, and only a small oral alkylating drug slips through. In the gut, a sarcoma once written off as chemo-resistant was tamed by the very same pill that rewrote leukaemia. One story about crossing a wall; another about hitting a single mutation dead-on.
Two operating rooms, decades apart. In the first, a neurosurgeon lifts a glioblastoma from the brain — but everyone knows some cells have already crept beyond the knife, hiding behind the blood–brain barrier, the very wall that guards the brain from toxins now guarding the tumour from our drugs. Only one small pill, temozolomide, is trusted to slip across that wall. In the second room, years earlier, a gastrointestinal stromal tumour — a gut sarcoma that chemotherapy barely touched — sits inoperable and spreading. Then a single tablet, imatinib, arrives: the same molecule that had just tamed a leukaemia. It jams the mutated switch driving the tumour, and the masses melt. One barrier, one mutation — two cancers taught us that where and how a drug reaches its target can matter as much as the drug itself.
The wall that protects and betrays: the blood–brain barrier
The brain is the best-defended organ in the body. Its capillaries are sealed by tight junctions — the blood–brain barrier — that keep out most large, water-loving, or protein-bound molecules. That is wonderful for keeping toxins away from neurons, and terrible when the enemy is a primary brain tumour like a glioma (a tumour of the brain's supporting glial cells), of which glioblastoma is the most aggressive form. A drug that cannot cross the barrier simply never reaches the tumour, no matter how good it looks in a test tube. This single fact reshapes the entire treatment plan.
So the backbone of glioblastoma care is built around what actually works together: maximal safe surgery to remove the bulk, then radiotherapy to the tumour bed, given alongside temozolomide — a small, lipophilic, oral alkylating agent that crosses the barrier and damages tumour DNA. This concurrent chemoradiation, followed by more temozolomide, is the modern standard. Bevacizumab, an anti-VEGF antibody, is used mainly for tumour-related swelling and at recurrence rather than to cure. Cross-link: temozolomide belongs to the Alkylating-agents chapter, and bevacizumab to the Monoclonal-antibodies chapter.
Temozolomide works by adding alkyl groups to DNA. Tumour cells fight back with a repair enzyme, MGMT, that erases exactly that damage. If the MGMT gene's promoter is methylated (switched off), the tumour makes little repair enzyme — so temozolomide hits harder and patients benefit more. MGMT methylation is therefore a predictive biomarker: it doesn't just describe the tumour, it forecasts response. Cross-link: this is the logic of the Precision-oncology chapter.
Corticosteroids are not anti-cancer, yet they are among the most useful drugs in neuro-oncology. Dexamethasone rapidly reduces the peritumoural oedema (the swelling around a brain tumour) that causes headache, drowsiness and raised intracranial pressure. A patient can improve within hours — before any tumour has shrunk — simply because the pressure is relieved. Cross-link: this crosses the Oncologic-emergencies chapter (raised ICP) and the Endocrine/Inflammation sections (glucocorticoid action).
Here is the twist most students miss. Most brain tumours seen in the clinic are not primary at all — they are metastatic, secondary deposits that have spread to the brain from another organ, most often lung, breast or melanoma. Brain metastases far outnumber primary gliomas. Crucially, you treat a brain metastasis according to its primary cancer (the systemic therapy for that lung or breast tumour) plus local control — surgery or focused radiosurgery — not as though it were a glioma. Getting this distinction wrong sends the whole plan in the wrong direction.
- The blood–brain barrier decides which systemic drugs can even reach a brain tumour.
- Glioblastoma standard: maximal safe surgery + radiotherapy + temozolomide (oral alkylator that crosses the barrier).
- MGMT promoter methylation predicts greater temozolomide benefit.
- Dexamethasone treats peritumoural oedema and raised intracranial pressure — supportive, not curative.
- Bevacizumab is used mainly for oedema and at recurrence, not to cure glioblastoma.
- Most brain tumours seen are metastatic — treat per the primary cancer plus local therapy.
Sarcomas: rare cancers of bone and soft tissue
Sarcomas are a diverse, uncommon family of cancers arising from mesenchymal (connective) tissues — bone, muscle, fat, cartilage and blood vessels — as opposed to the far more common carcinomas that arise from epithelium. Because they are rare and varied, care is centred at specialist units, and the mainstay for many soft-tissue sarcomas is still cytotoxic chemotherapy: an anthracycline, doxorubicin, as the backbone, often combined with ifosfamide (an alkylating agent) for a harder hit. Cross-link: doxorubicin sits in the Anthracyclines chapter and ifosfamide in the Alkylating-agents chapter.
Then came the exception that rewrote the rules. Gastrointestinal stromal tumour (GIST) is the classic targeted-therapy success in sarcoma. Most GISTs are driven by an activating mutation in a single receptor tyrosine kinase — KIT, or less often PDGFRA — a switch stuck permanently ON, telling the cell to grow. Conventional chemotherapy barely works on GIST. But imatinib, a kinase inhibitor that blocks exactly that switch, produces dramatic, durable responses. It is the very same drug that transformed chronic myeloid leukaemia (CML) by blocking a different fused kinase. Cross-link: imatinib runs through the Hematology CML chapter and the Kinase-inhibitors chapter.
GIST also teaches the modern rhythm of targeted therapy: resistance. When a GIST stops responding to imatinib, later-line kinase inhibitors such as sunitinib and then regorafenib are used as the tumour evolves new resistance mutations. Beyond GIST, other soft-tissue sarcomas have their own targeted options — for example pazopanib, an oral multi-kinase inhibitor, for certain non-adipocytic soft-tissue sarcomas after chemotherapy. The lesson: sarcoma is not one disease with one drug, but many subtypes each with its own vulnerability.
Bone sarcomas follow a different playbook, shaped by their patients: osteosarcoma and Ewing sarcoma strike mainly children, adolescents and young adults, and they are treated aggressively for cure. The approach is intensive multi-drug chemotherapy — combinations built around agents such as doxorubicin, high-dose methotrexate and cisplatin for osteosarcoma, and vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide for Ewing — wrapped around surgery (and radiotherapy in Ewing). The intensity reflects both the biology and the young, fit patients who can tolerate it.
- Sarcomas arise from mesenchymal tissue (bone, muscle, fat) — rare and heterogeneous, managed in specialist centres.
- Doxorubicin ± ifosfamide is the classic backbone for many soft-tissue sarcomas.
- GIST is KIT/PDGFRA-driven and the targeted success story — imatinib, then sunitinib/regorafenib on resistance.
- Imatinib is the same kinase inhibitor that transformed CML — one drug, two very different cancers.
- Other subtypes have their own targeted agents (e.g., pazopanib after chemotherapy).
- Bone sarcomas (osteosarcoma, Ewing) hit the young and use intensive multi-drug chemo around surgery.
- Choosing a systemic drug for a brain tumour without asking whether it crosses the blood–brain barrier.
- Treating every brain tumour as primary. Most are metastatic — identify and treat the primary cancer plus local therapy.
- Reaching for conventional chemotherapy in GIST. It is a targetable, imatinib-sensitive sarcoma driven by KIT/PDGFRA, not a chemo disease.
- Forgetting that dexamethasone relieves symptoms of oedema and raised pressure but does not shrink the tumour itself.
A gastrointestinal stromal tumour (GIST) is best treated with which of the following, reflecting its underlying biology?
- The blood–brain barrier limits which drugs reach a brain tumour; glioblastoma standard is surgery + radiotherapy + temozolomide.
- MGMT methylation predicts temozolomide benefit; dexamethasone treats oedema/raised pressure; bevacizumab for oedema and recurrence.
- Most brain tumours seen are metastatic — treat per the primary cancer plus local therapy.
- Sarcomas: doxorubicin ± ifosfamide backbone; GIST is the KIT/PDGFRA-driven imatinib success; bone sarcomas use intensive multi-drug chemo in the young.
- NCCN Clinical Practice Guidelines in Oncology — Central Nervous System Cancers (glioblastoma: surgery, radiotherapy, temozolomide, MGMT).
- Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med.
- ESMO Clinical Practice Guidelines — High-grade glioma and brain metastases: diagnosis, treatment and follow-up.
- NCCN Clinical Practice Guidelines in Oncology — Gastrointestinal Stromal Tumors (KIT/PDGFRA, imatinib, sunitinib, regorafenib).
- ESMO Clinical Practice Guidelines — Soft tissue and visceral sarcomas; Bone sarcomas (osteosarcoma, Ewing).
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Alkylating agents and protein kinase inhibitors.
